anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.

Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
Eligibility criteria:
Inclusion Criteria:

Patients scheduled to undergo unilateral total knee arthroplasty.
American Society of Anesthesiology (ASA) Physical Class 1-3.
BMI <40 kg/m2

Exclusion Criteria:

Revision surgery.
Bilateral total knee arthroplasty.
Unicompartmental knee arthroplasty.
Patients with a contraindication to regional anesthesia. This includes abnormal clotting, skin infection in groin or near the back, the presence of neurological disorders or anatomical abnormalities of the vertebral column.
Contraindications or known drug interactions with dexamethasone.

Use of any of the following medications within the times specified before surgery:

Long-acting opioid medication within 3 days.
Any opioid medication within 24 hours.
Body weight less than 50 kilograms (~110 pounds).
Planned administration of another investigational product or procedure during the subject's participation in this study.
Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postoperative course.
Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function (Ejection fraction under 35%), epilepsy, myasthenia gravis), severe renal impairment (creatinine > 1.8), comorbid conditions associated with an immunocompromised status, such as blood dyscrasias, HIV/AIDS, or recent chemotherapy.
Intervention: SALICYLIC ACID
Trial phase: Phase 2
ATC code: D01AE12 | N02BA04 | N02BA12 | S01BC08
SMILES: O=C(O)c1ccccc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Multiple oral doses of YPL-001 80 mg BID on Days 1 - 55
Eligibility criteria:
Inclusion Criteria:

Adult males and/or females, 30 to 85 years of age (inclusive).
History of COPD for at least 12 months prior to screening.
Diagnosed with COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with symptoms compatible with COPD for at least 12 months prior to screening.
Classified as moderate to severe COPD based on the current severity classification GOLD Stage 2-3 disease in terms of post-bronchodilator spirometry at screening
etc.

Exclusion Criteria:

History of life-threatening COPD including respiratory arrest, intensive care unit admission and/or requiring intubation.
History of more than 2 hospitalizations for COPD within 12 months prior to screening.
Presentation of an acute exacerbation of COPD that will be associated with increase sputum volume or change in sputum color within 4 weeks before Day 1 of the Run-in Period.
Evidence of pulmonary heart disease, or clinically significant pulmonary hypertension.
etc.
Intervention: SALICYLIC ACID
Trial phase: Phase 2
ATC code: D01AE12 | N02BA04 | N02BA12 | S01BC08
SMILES: O=C(O)c1ccccc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Multiple oral doses of YPL-001 160 mg BID on Days 1 - 55
Eligibility criteria:
Inclusion Criteria:

Adult males and/or females, 30 to 85 years of age (inclusive).
History of COPD for at least 12 months prior to screening.
Diagnosed with COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with symptoms compatible with COPD for at least 12 months prior to screening.
Classified as moderate to severe COPD based on the current severity classification GOLD Stage 2-3 disease in terms of post-bronchodilator spirometry at screening
etc.

Exclusion Criteria:

History of life-threatening COPD including respiratory arrest, intensive care unit admission and/or requiring intubation.
History of more than 2 hospitalizations for COPD within 12 months prior to screening.
Presentation of an acute exacerbation of COPD that will be associated with increase sputum volume or change in sputum color within 4 weeks before Day 1 of the Run-in Period.
Evidence of pulmonary heart disease, or clinically significant pulmonary hypertension.
etc.
Intervention: Ibuprofen
Trial phase: Phase 3
ATC code: C01EB16 | G02CC01 | M01AE01 | M01AE14 | M01AE51 | M02AA13 | N02AJ08 | N02AJ19 | R02AX02
SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 91
Group description: Each tablet containing 400mg of ibuprofen

Ibuprofen: Ibuprofen
Eligibility criteria:
Inclusion Criteria:

Any participant in a RacingThePlanet sanctioned event who understands the consent form in English.

Exclusion Criteria:

Allergic to any form of non-steroidal anti-inflammatory
Taken a NSAID or steroid in prior 12 hours
1 kidney
Known to be pregnant or suspected to be pregnant
Intervention: Bis(choline)tetrathiomolybdate
Trial phase: Phase 2
SMILES: C[N+](C)(C)CCO.C[N+](C)(C)CCO.S=[Mo]=S.[SH-].[SH-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: Treatment Period: ALXN1840 at individualized doses ranging from 15 to 60 mg per day. Dose increases or dose reductions were dependent on the individual NCC concentrations adjusted for Mo plasma concentration. ALXN1840 may have been administered every other day, once daily, or twice daily, depending on individualized dosing regimen, for 24 weeks.

Extension Period: Participants continued the same ALXN1840 daily dose maintained at Week 24 of the Treatment Period and the same dosing regimen. During the Extension Period, no up-titration was made unless NCC concentrations adjusted for Mo plasma concentration did not remain stable within (or below) the reference range.
Eligibility criteria:
Inclusion Criteria:

Able to understand and willing to comply with study procedures, restrictions, and requirements, as judged by the Investigator.
Newly established diagnosis of WD by Leipzig-Score ≥ 4 documented by testing as outlined in 2012 European Association for the Study of the Liver Wilson Disease Clinical Practice Guidelines.
NCC levels within or above the normal reference range (0.8 to 2.3 micromole).
Willing to undergo 48 hour washout from current WD treatment

Exclusion Criteria:

Treatment for greater than 24 months for WD with chelation therapy (for example, penicillamine, trientine hydrochloride) or zinc therapy.
Decompensated hepatic cirrhosis.
Model for End-Stage Liver Disease score > 11.
Modified Nazer score > 6.
Gastrointestinal bleed within past 6 months.
Alanine aminotransferase > 5 x upper limit of normal.
Marked neurological disease requiring either nasogastric feeding or intensive in-patient medical care.
Severe anemia with a hemoglobin < 9 grams/deciliter.
Intervention: Clomid
Trial phase: Phase 2
SMILES: CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Patients receiving clomiphene citrate

Clomiphene Citrate: Clomiphene citrate, 50 mg, orally for three months

No adverse events were reported
Eligibility criteria:
Inclusion Criteria:

patients with active acromegaly on regular use of a stable dose of Octreotide-LAR and/or cabergoline for at least one year,
Insulin like growth factor 1 above the reference range during the last year of follow-up and
testosterone levels within or below the third inferior tertile of normality.

Exclusion Criteria:

radiotherapy in the last 10 years, previous venous embolism (including family members),
previous prostatic cancer or symptomatic benign hypertrophy,
triglyceride levels above 400 mg/dL,
renal failure defined by estimative of renal filtration below 30 ml/min,
liver disease defined by hepatic enzymes 3 times above normal limit,
active oncologic disease in the last 10 years and previous cardiac or cerebrovascular disease.
Intervention: Amantadine Hydrochloride
Trial phase: Phase 3
SMILES: Cl.NC12CC3CC(CC(C3)C1)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 37
Group description: 340 mg dose of ADS-5102 (amantadine HCl extended release): oral capsules administered once nightly at bedtime for 13 weeks
Eligibility criteria:
Inclusion Criteria:

Signed a current IRB/REB/IEC-approved informed consent form;
Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria;
On a stable regimen of antiparkinson's medications for at least 30 days prior to screening, including a levodopa preparation administered not less than three times daily, and willing to continue the same doses and regimens during study participation;
Following diary training, the subject is willing and able to understand and complete the 24-hour PD home diary (trained caregiver/study partner assistance allowed);
Any other current and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must have been at a stable dose and regimen for at least 30 days prior to screening, and subject must be willing to continue the same doses and regimens during study participation (this criterion does not apply to medications that are being taken pre-study only on an as-needed basis);

Exclusion Criteria:

History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain stimulation);
History of seizures within 2 years prior to screening;
History of stroke or TIA within 2 years prior to screening;
History of cancer within 5 years prior to screening, with the following exceptions: adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer, in situ cervical cancer, or other definitively treated cancer that is considered cured;
Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening;
If female, is pregnant or lactating;
If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment, using one of the following: barrier methods (diaphragm or partner using condoms plus use of spermicidal jelly or foam, preferably double-barrier methods); oral or implanted hormonal contraceptive; intrauterine device (IUD); or vasectomized male partner;
Treatment with an investigational drug or device within 30 days prior to screening;
Treatment with an investigational biologic within 6 months prior to screening;
Current participation in another clinical trial;
Intervention: Digoxin
Trial phase: Not Applicable
ATC code: C01AA05
SMILES: [H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@@H](C5=CC(=O)OC5)CC[C@@]43O)[C@@]1(C)CC[C@H](O[C@H]1C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4C[C@H](O)[C@H](O)[C@@H](C)O4)[C@@H](C)O3)[C@@H](C)O1)C2
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 60
Group description: Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion

Digoxin (transvaginal administration): Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a "Procedure/Surgery" type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.
Eligibility criteria:
Inclusion Criteria:

Age greater than or equal to 18 years
Singleton viable gestation
Identifying as primarily English-speaking
Body mass index less than 40 kilograms/meters squared
Already a consented patient for second-trimester abortion procedure with digoxin to be performed for termination of pregnancy at the study site
No medical contraindication to digoxin (i.e., no cardiac dysfunction, no renal dysfunction, no hypersensitivity to digoxin)
Intervention: Digoxin
Trial phase: Not Applicable
ATC code: C01AA05
SMILES: [H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@@H](C5=CC(=O)OC5)CC[C@@]43O)[C@@]1(C)CC[C@H](O[C@H]1C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4C[C@H](O)[C@H](O)[C@@H](C)O4)[C@@H](C)O3)[C@@H](C)O1)C2
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 60
Group description: Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion

Digoxin (transabdominal administration): Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a "Procedure/Surgery" type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.
Eligibility criteria:
Inclusion Criteria:

Age greater than or equal to 18 years
Singleton viable gestation
Identifying as primarily English-speaking
Body mass index less than 40 kilograms/meters squared
Already a consented patient for second-trimester abortion procedure with digoxin to be performed for termination of pregnancy at the study site
No medical contraindication to digoxin (i.e., no cardiac dysfunction, no renal dysfunction, no hypersensitivity to digoxin)
Intervention: Pregabalin
Trial phase: Not Applicable
ATC code: N02BF02 | N03AX16
SMILES: CC(C)C[C@H](CN)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Lyrica 300 mg: Lyrica 300 mg per day
Eligibility criteria:
Inclusion Criteria:

Patients being treated for oropharyngeal cancer with undergoing concurrent chemotherapy and radiation therapy (photons) for a histological diagnosis of squamous cell carcinoma to the head and neck at the University of Pennsylvania
Age at least 18 years old
Treatment entails significant risk for symptomatic mucositis likely to require opioid analgesia, as per the discretion of treating physician/NP
Subjects are capable of giving informed consent

Exclusion Criteria:

Patients anticipated to receive radiation therapy with Protons
History of hypersensitivity to pregabalin or gabapentin
History of seizure or currently taking anti-epileptic medication
Creatinine clearance of less than 30 mL/min by Cockcroft-Gault estimate
Has another painful condition requiring chronic use of opioid analgesic, gabapentin, or pregabalin
History of serious mood disorder or attempted suicide as determined by patients history and physical and by using theDepression Screening
Subjects with a score of greater than 10 or those answering #5 with scores greater than a "0" will be deemed ineligible to be enrolled on study
History of angioedema
New York Heart Association class III or IV heart failure
Platelets of less than 150 mg/dL or history of thrombocytopenia
The patient has any uncontrolled intercurrent illness including but not limited to psychiatric illness/social situations that would limit compliance or interfere with their ability to participate
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Application of 20ml of normal saline (NaCl 0.9%) topically after implantation of prosthesis; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.

Normal saline (0.9% NaCl): Administered in all 3 groups
Eligibility criteria:
Inclusion Criteria:

All patients at the participating sites on the waiting list for a unilateral total knee joint replacement

Exclusion Criteria:

Patients with a history or risk of thrombosis
Active thromboembolic disease such as deep vein thrombosis, pulmonary embolism and cerebral thrombosis
Subarachnoid haemorrhage
Hypersensitivity to tranexamic acid or any of its ingredients.
Refusal of blood products
Colour blindness
Complex hematologic disorders requiring manipulation
Coagulopathy
Pregnant and Lactating Women
Anti-coagulant therapy pre-operatively within 5 days of surgery (warfarin, dabigatran, heparin)
Severe renal failure (eGFR <29)
Intervention: Pioglitazone
Trial phase: Phase 2
ATC code: A10BD05 | A10BD06 | A10BD09 | A10BD12 | A10BG03
SMILES: CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and 30 mg of Actos in capsules administered orally 1 capsule per day for 3 months

actos: 30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)
Eligibility criteria:
Inclusion Criteria:

Patients on CHD undergoing three time a week therapy for more than 6 months;
Age 21 years old;
Acceptable dialysis adequacy (spKt/V > 1.2);
A patent, well-functioning, arterio-venous dialysis access;
Ability to give informed consent;
Life expectancy greater than 6 months;
BMI >=20 and <=45.

Exclusion Criteria:

Pregnancy;
Intolerance or allergy to the study medication (including the metabolic clamp studies);
Severe, unstable, active inflammatory disease (active infection, active connective tissue disorder), active cancer or cancer history in the prior 5 years except skin cancer, AIDS-HIV, active or history of liver disease (including hepatitis B virus and hepatitis C virus);
Hospitalization or infection within 1 month prior to the study;
Patients receiving steroids and/or other immunosuppressive agents (Prednisone > 5 mg/day; excluding inhaled and topical steroids);
Diabetes Mellitus on insulin therapy;
Previous history of tuberculosis (TB) with or without documented adequate therapy;
Patients with recent close exposure to an individual with active TB;
Females using oral contraceptives;
Patients with New York Heart Association (NYHA) Class III or IV heart failure;
Patients with a history of angina, myocardial infarction, transient ischemic attacks, or strokes within the last 6 months.
Intervention: Technetium Tc-99m
Trial phase: Phase 3
SMILES: [Tc]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 49
Group description: intradermal injection of 20 MBq of technetium 99 before breast surgery

isotope: One injection, 20 MBq techntium99, intradermal use
Eligibility criteria:
Inclusion Criteria:

Histologically proved infiltrating breast cancer (ductal, lobular carcinoma…) or a carcinoma in-situ with an elevated risk of micro-invasion. (High grade with necrosis, radiologically evaluated size more than 40mm, or immediate mastectomy…)
Unifocal or multifocal but in same quarter
Size < 5cm clinically palpable or not
Clinically or ultrasound axillary N0
Isotopic sentinel node detection
Adult patient
Signed informed consent by patient or legally responsable authority
Patient registered to a social security system
No surgical contra-indication

Exclusion Criteria:

Mammary carcinoma recurrence
Previous same side mammary reduction
Previous lumpectomy
Contra-indication to surgery
Pregnant or breast feeding patient
Denial of participation
Intervention: Dalfampridine
Trial phase: Phase 2
ATC code: N07XX07
SMILES: Nc1ccncc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 11
Group description: 22 weeks administration of 4-aminopyridine. The mean dose provided to the patients was 0.63 ± 0.05 mg per kg of body weight.
Eligibility criteria:
Inclusion Criteria: Patients with multiple sclerosis (MS) are eligible for the study if they meet the following criteria:

Relapsing recurrent MS with an evolution of at last 6 months before the study began.
Both males and females, aged 20 - 65 years
Neurologic Expanded Disability Status Scale (EDSS) 3 - 7
Who are in first-line immunomodulatory therapy and have a stable disease
No more than one outbreak per year.
The absence of antiepileptic antecedent and electroencephalogram without epileptic activity.
For females: postmenopausal or surgically sterile, or using an acceptable method of birth control

Exclusion Criteria:

History of cardiovascular disease (syncope, arrhythmia, or myocardial infarction within the last two years), systolic blood pressure greater than 150 or less than 70 mm Hg, diastolic blood pressure greater than 110 or less than 50 mm Hg, or heart rate greater than 110 or less than 50 beats/minute; impaired hepatic function (total hepatic enzyme or bilirubin levels greater than 2 times the upper limits of normal) or impaired renal function (creatinine level greater than 2 times the upper limits of normal) less than 6 months before the study
Known allergy to pyridine-containing drugs
Neurologic, degenerative, or psychiatric disorders that would impair the patient's ability to complete the protocol
Any illness or abnormality that would jeopardize patient safety or interfere with the conduct of the study
History of substance abuse
Inability to discontinue excluded concomitant drug therapy
Intervention: Ticagrelor
Trial phase: Phase 4
ATC code: B01AC24
SMILES: CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Patients to be discharged on ticagrlore regiment of 90mg twice a day for 6 months.

Ticagrelor
Eligibility criteria:
Inclusion Criteria:

• Female (post menopausal or surgically sterile) and/or male aged 18 years or older

Multi-vessel coronary artery disease CAD
Statin therapy for minimum of 6 weeks prior to enrollment in the study with no plan for further adjustment
Non-emergent PCI for ACS with stent placement requiring dual-antiplatelet therapy
Ability to safely perform NIRS/IVUS for a concomitant non-culprit lesion with diameter stenosis ≥50% that was not treated with PCI
Willing and able to sign informed consent and participate in follow-up

Exclusion Criteria:

Thienopyridine or ticagrelor use in the last month
Need for coronary artery bypass surgery or other surgeries during the follow-up period
Documented medication non-compliance
Chronic inflammatory disorder or treatment with anti-inflammatory or immunosuppressive drugs
Prior or current malignancy within the last 5 years
Concomitant severe illness or reduced life expectancy that will prevent follow-up cardiac catheterization
Active infection
Pregnant or lactating women
End-stage renal disease
History of intracranial hemorrhage
Active pathological bleeding
Known severe hepatic impairment
Known hypersensitivity to ticagrelor